COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study
Interactive Journal of Medical Research · 2026-06-02 · 15 · e80263-e80263
DOI: 10.2196/80263 ↗At a glance
Kohortenstudie in Interactive Journal of Medical Research, published online on 2026-06-02. Written by Jacqueline K Kueper and 11 co-authors. Institution: Scripps Research Translational Institute, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, United States, 1 858-784-10…. 31 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Observation of COVID-19 rebound after nirmatrelvir plus ritonavir (NPR) has driven important questions surrounding one of the only direct-acting antiviral treatments for COVID-19.
Objective
The objective of this study was to examine the epidemiology of COVID-19 rebound among COVID-19–positive outpatients in the United States who independently decided whether or not to take NPR.
Methods
This prospective, decentralized observational cohort study was conducted from August 2022 through December 2023 and included frequent proctored COVID-19 rapid antigen tests and self-report symptom surveys for 15 days. The primary outcome was the incidence of viral and symptom rebound. Secondary outcomes included time to initial viral and symptom clearance, rebound probability among patients who cleared by day 15, and symptom frequency.
Results
Of 917 consenting participants, 669 (73%) were eligible for inclusion in the analysis (n=443, 66% in the NPR group; n=226, 34% in the control group). The mean age was 46.1 (SD 12.9) years, 62.6% (n=419) of participants were female, and 49.2% (n=329) had at least one preexisting condition. Overall, 15-day cumulative incidence was higher in the NPR group than the control group for both viral (70/443, 15.8% vs 12/226, 5.3%) and symptom (73/443, 16.5% vs 19/226, 8.4%) rebound. Time to initial viral and symptom clearance was similar between groups, and among those who experienced clearance by day 15, the probability of viral rebound (NPR: 19.1%, 95% CI 15.1%-24.0% vs control: 7%, 95% CI 4.0%-12.6%; P
Subjects
Author keywords
Authors and institutions
- Scripps Research Translational Institute, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037, United States, 1 858-784-1000.
- Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA, United States.
- Care Evolution, Ann Arbor, MI, United States.
- eMed, Miami, FL, United States.
- Immune Observatory, Boston, MA, United States.
Cite
APA
Kueper, J. K., Kottilil, K., Quer, G., Chiang, D. C., Spencer, E. G., Purushotham, J., Ramos, E., Roumani, L., Andersen, K. G., Topol, E. J., Pandit, J. A., & Mina, M. J. (2026). COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study. Interactive Journal of Medical Research, 15, e80263-e80263. https://doi.org/10.2196/80263
Vancouver
Kueper JK, Kottilil K, Quer G, Chiang DC, Spencer EG, Purushotham J, et al. COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study. Interactive Journal of Medical Research. 2026;15:e80263-e80263. doi:10.2196/80263
BibTeX
@article{Kueper2026,
author = {Kueper, Jacqueline K and Kottilil, Kalyani and Quer, Giorgio and Chiang, Danielle C and Spencer, Emily G and Purushotham, Jyothi and Ramos, Edward and Roumani, Leila and Andersen, Kristian G and Topol, Eric J and Pandit, Jay A and Mina, Michael J},
title = {COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study},
journal = {Interactive Journal of Medical Research},
year = {2026},
volume = {15},
pages = {e80263--e80263},
doi = {10.2196/80263}
}
EUVIMED